Invivyd, Inc. (IVVD)

Invivyd, Inc. is a commercial-stage biopharmaceutical company whose mission is to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from circulating viral threats, beginning with SARS-CoV-2. Its proprietary INVYMAB platform approach combines viral surveillance and predictive modeling with advanced antibody engineering to generate new monoclonal antibodies (mAbs) in series, keeping pace with evolving viruses. The company has devoted substantially all of its resources to organizing and staffing, building intellectual property, research and development, arranging third-party manufacturing, and raising capital.

Its first product is PEMGARDA (pemivibart), a half-life extended mAb given by intravenous injection. The FDA granted it emergency use authorization on March 22, 2024 for pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 and older, at least 40 kg) who are moderately to severely immunocompromised and unlikely to mount an adequate response to vaccination. Authorization followed positive initial results from the CANOPY Phase 3 trial of VYD222, which enrolled about 750 participants in two cohorts and used calculated serum neutralizing titers as a correlate of protection in an immunobridging approach agreed with the FDA. The next pipeline program is VYD2311, nominated as a drug candidate in January 2024 and optimized for potency against recent lineages such as BA.2.86 and JN.1. Invivyd also plans to apply the platform to other viral diseases such as influenza, and it evaluates in-licensing opportunities. The company says all previously authorized COVID-19 therapeutic mAbs other than PEMGARDA have lost U.S. authorization as variants emerged.

PEMGARDA targets immunocompromised people, a group for which the company says vaccines have limited effectiveness and antivirals can have significant drug-drug interactions. The company is initially commercializing in the U.S. through a focused field sales organization aimed at healthcare practitioners and institutions that care for the highest-risk patients, and it may expand to other immunocompromised groups over time. Unlike earlier COVID-19 EUA products sold under federal advance purchase agreements, PEMGARDA follows a traditional commercial model in which customers buy from wholesalers or distributors and product is shipped to provider institutions and clinics that bill health insurers. The company continues to explore partnerships and collaborations to extend its reach.

Invivyd relies on partners, consultants and contract research organizations for discovery, nonclinical, clinical and commercial activities, and on contract testing laboratories and contract development and manufacturing organizations for CMC work. It has engaged WuXi Biologics (Hong Kong) Limited for development and for clinical and commercial supply of its product candidates, and believes it has secured sufficient capacity for anticipated initial PEMGARDA demand. It has exclusive access to Adimab's B-cell mining and antibody engineering capabilities for coronavirus antibody discovery, and since 2022 has built dedicated internal laboratory space and a larger research team. It also hired its own sales, marketing, market access and medical affairs leaders and uses contract organizations for some field roles. The text does not identify competitors or the headquarters location.